GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (NAS:GHRS) » Definitions » PensionAndRetirementBenefit

GHRS (GH Research) PensionAndRetirementBenefit : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is GH Research PensionAndRetirementBenefit?

GH Research's PensionAndRetirementBenefit for the quarter that ended in Mar. 2025 was $0.00 Mil.


GH Research PensionAndRetirementBenefit Historical Data

The historical data trend for GH Research's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GH Research PensionAndRetirementBenefit Chart

GH Research Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PensionAndRetirementBenefit
Get a 7-Day Free Trial - - - - -

GH Research Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GH Research PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


GH Research Business Description

Industry
Traded in Other Exchanges
Address
Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.